Piśmiennictwo

Piśmiennictwo:

[1] American College of Occupational and Environmental Medicine (ECOEM) Guidelines for chronic use of opioids. www.acoem.org/ Guidelines_Opioids.aspx. Accessed November 8, 2013.
[2] Atluri S, Akbik H, Sudarshan G.: Prevention of Opioid Abuse in chronic Non-cancer pain: An Algorithme, Evedence Based Approach. Pain Physician 2012; 15: ES177-ES 189.
[3] Australian and New Zealand College of Anaesthetists Faculty of Pain Medicine.: Principles regarding the use of opioid analgesics in patients with chronic noncancer pain. www.fpm.anzca.edu.au/ resources/professional-documents/documents/PM1%202010.pdf. Accessed December 8, 2013.
[4] Ballantyne JC, LaForge KS.: Opioid dependence and addiction during opioid treatment of chronic pain. Pain 2007; 129(3): 235-255.
[5] Ballantyne JC, Mao J.: Opioid therapy for chronic pain. N Engl J Med 2003; 349(20): 1943-1953.
[6] Ballantyne J, Tauben DJ.: Expert Decision Making on Opioid Treatment. Oxford University Press, Oxford 2013.
[7] Baron MJ, McDonald PW.: Significant pain reduction in chronic pain patients after detoxification from high-dose opioids. J Opioid Manag. 2006 Sep-Oct;2(5):277-82
[8] Becker N, Sjogren P, Bech P, Olsen AK, Eriksen J.: Treatment outcome of chronic non-malignant pain patients managed in a danish multidisciplinary pain centre compared to general practice: a randomised controlled trial. Pain 2000; 84(2-3): 203-211.
[9] Berna C, Kulich RJ, Rathmell JP.: Tapering Long-term Opioid Therapy in Chronic Noncancer Pain: Evidence and Recommendations for Everyday Practice 2015; 90: 828-842.
[10] Bigal ME, Lipton RB.: Excessive opioid us e and the development of chronic migraine. Pain 2009; 142(3): 179-182.
[11] Blagden M, Hafer J, Duerr H, Hopp M, Bosse B.: Long-term evaluation of combined prolonged-release oxycodone and naloxone in patients with moderate-to-severe chronic pain: pooled analysis of extension phases of two Phase III trials. Neurogastroenterol Motil 2014; 26(12): 1792-801. doi: 10.1111/nmo.12463. Epub 2014 Oct 23.
[12] Bohnert AS, Valenstein M, Bair MJ, Ganoczy D, McCarthy JF, Ilgen MA, Blow FC.: Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA 2011; 305: 1315-21.
[13] Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D.: Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J. Pain 2006; 10(4): 287-333.
[14] Breivik H, Ljosaa TM, Stengaard-Pedersen K.: A 6-months, randomised, placebo-controlled evaluation of efficacy and tolerability of a low-dose 7-day buprenorphine transdermal patch in osteoarthritis patients naive to potent opioids. Scand J Pain 2010 (1): 122-141.
[15] Brensilver M, Tariq S, Shoptaw S.: Prim Care 2012; 39 (4): 661-669. doi: 10.1016/j.pop.2012.08.007.
[16] British Pain Society.: Recommendations for the appropriate use of opioids for persistent non-cancer pain. A consensus statement prepared on behalf of the Pain Society, the Royal College of Anaesthetists, the Royal College of General Practitioners and the Royal College of Psychiatrists. London, UK: The British Pain Society; 2004.
[17] British Pain Society. Opioids for persistent pain: Good practice. A consensus statement prepared on behalf of the British Pain Society, the Royal College of Anaesthetists, the Royal College of General Practitioners and the Faculty of Addictions of the Royal College of Psychiatrists. The British Pain Society, London, UK, January 2010. www.britishpainsociety.org/book_opioid_main.pdf. Accessed November 8, 2013.
[18] Busse JW, Schandelnaier S, Kamaleldin M, Hsu S, Riva JJ, Per Olav Vandvik, Tsoi L, Larn T, Montoya L, Kunz R, Maladrino A, Bhatnagar N, Mulla SM, Lopes LC, Soobiah Ch, Wong A, Buckley N, Sessler D, Guyatt GH.: Opioids for chronic non-cancer pain: a protocol for a systematic review of randomized controlled trials Systematic Reviews 2013; 2: 66.
[19] Butler SF, Budman SH, Fernandez KC, Houle B, Benoit C, Katz N, Jamison RN.: Opracowanie i walidacja miary bieżącego niewłaściwego stosowania opioidów. Ból 2008, 9(2): 27-40.
[20] Buynak R, Shapiro DY, Okamoto A. et al.: Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. Expert Opin Pharmacother 2010; 11(11): 1787-1804.
[21] Caldwell JR, Hale ME, Boyd RE. et al.: Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial. J Rheumatol 1999; 26: 862-869.
[22] Caldwell JR, Rapoport RJ, Davis JC. et al.: Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, doubleblind trial and an open-label extension trial. J Pain Symptom Manage 2002; 23: 278-291.
[23] Centers for Disease Control and Prevention. CDC grand rounds: Prescription drug overdoses – a U.S. epidemic. MMWR Morb Mortal Wkly Rep 2012; 61: 10-13.
[24] Chaparro LE, Furlan AD, Deshpande A, Mailis-Gagnon A, Atlas S, Turk DC.: Opioids compared to placebo or other treatments for chronic low-back pain. Cochrane Database Syst Rev 2013; 27; 8: CD004959. doi: 10.1002/14651858.CD004959.pub4.
[25] Chaparro LE, Furlan AD, Deshpande A, Mailis-Gagnon A, Atlas S, Turk DC.: Opioids compared with placebo or other treatments for chronic low back pain: an update of the Cochrane Review. Spine (Phila Pa 1976). 2014; 1; 39(7): 556-63. doi: 10.1097/ BRS.0000000000000249.
[26] Chelminski PR, Ives TJ, Felix KM, Prakken SD, Miller TM, Perhac JS. et al.: A primary care, multi-disciplinary disease management program for opioid-treated patients with chronic non-cancer pain and a high burden of psychiatric comorbidity. BMC Health Services Research 2005; 13; 5(1): 3.
[27] Cheung CW, Qiu Q, Choi SW, Moore B, Goucke R, Irwin M.: Chronic Opioid Therapy for Chronic Non-Cancer Pain: A Review and Comparison of Treatment Guidelines. Pain Physician 2014; 17:401- 414 • ISSN 1533-3159.
[28] Chou R, Clark E, Helfand M.: Comparative efficacy and safety of long- -acting oral opioids from high-dose opioids. J Opioid Manag 2006; 2:277-282.
[29] Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, Donovan MI, Fishbain DA, Foley KM, Fudin J, Gilson AM, Kelter A, Mauskop A, O’Connor PG, Passik SD, Pasternak GW, Portenoy RK, Rich BA, Roberts RG, Todd KH, Miaskowski C.: American Pain Society–American Academy of Pain Medicine Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic non cancer pain. J Pain 2009 [A]; 10: 113-130.
[30] Chou R, Fanciullo GJ, Fine PG, Miaskowski C, Passik SD, Portenoy RK.: Opioids for chronic noncancer pain: Prediction and identification of aberrant drug related behaviors: A review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain 2009 [B]; 10:131-146.
[31] Chou R, Judith A, Turner JA, Devine EB, Hansen RN, Sullivan SD, Blazina I, Dana T, Bougatsos C, Deyo RA.: The Effectiveness and Risks of Long-Term Opioid Therapy for Chronic Pain: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015; 162: 276-286. doi: 10.7326/M14- 2559.
[32] CHPL transtec, oksykodon, fentanyl, chronic non-cancer pain: A systematic review. J Pain Symptom Manage 2003; 26: 1026-1048.
[33] Chugh SS, Socoteanu C, Reinier K. et al.: A community-based evaluation of sudden death associated with therapeutic levels of methadone. Am. J. Med 2008; 121: 66-71.
[34] Cloutier C, Taliano J, O’Mahony W. et al.: Controlled-release oxycodone and naloxone in the treatment of chronic low back pain: a placebo-controlled, randomized study. Pain Res Manag 2013; 18(2): 75-82.
[35] Collins SL, Moore RA, McQuay HJ.: The visual analogue pain intensity scale: what is moderate pain in millimetres? Pain 72; 1997: 95-97.
[36] da Costa BR, Nüesch E, Kasteler R, Husni E, Welch V, Rutjes AW, Jüni P.: Oral or transdermal opioids for osteoarthritis of the knee or hip. Cochrane Database Syst Rev. 2014 Sep 17; 9: CD003115. doi: 10.1002/14651858.CD003115.pub4.
[37] Daniell HW.: DHEAS deficiency during consumption of sustained- -action prescribed opioids: evidence for opioid-induced inhibition of adrenal androgen production. J. Pain 2006; 7: 901-907.
[38] Daniell HW.: Hypogonadism in men consuming sustained-action oral opioids. J. Pain 2002; 3: 377-384.
[39] Dasgupta N, Kramer ED, Zalman MA, Carino S Jr, Smith MY, Haddox JD, et al.: Association between non-medical and prescriptive usage of opioids. Drug Alcohol Depend 2006; 28; 82(2): 135-142.
[40] Daut RL, Cleeland CS, Flanery RC.: The development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 1983; 17: 197-210.
[40] Daut RL, Cleeland CS, Flanery RC.: The development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 1983; 17: 197-210.
[41] Deshpande A, Furlan A, Mailis-Gagnon A, Atlas S, Turk D.: Opioids for chronic low back pain (review). Cochrane Database Syst Rev 2007; 3: CD004959.
[42] Deyo RA, Von Korff M, Duhrkoop D.: Opioids for low back pain. BMJ 2015; 5, 350: g6380. doi: 10.1136/bmj.g6380.
[43] De Walden–Gałuszko K, Majkowicz M.: Psychologiczno–kliniczna ocena bólu przewlekłego. Akademia Medyczna w Gdańsku, Gdańsk 2003.
[44] Dobrogowski J, Kołłątaj M.: Ocena kliniczna chorego z bólem. W: Leczenie bólu. (ed. Wordliczek J, Dobrogowski J.) Wydawnictwo Lekarskie PZWL, Warszawa 2011: 233-262.
[45] Dobrogowski J, Sedlak K.: Ocena kliniczna chorego z bólem przewlekłym. W: Dobrogowski J, Kuś M, Sedlak K, Wordliczek J. Ból i jego leczenie. Springer PWN, Warszawa 1996: 46-58.
[46] Dobrogowski J, Wordliczek J, Hilgier M.: Zasady stosowania silnych w leczeniu bólu nie nowotworowego. Ból 2004; 5(3): 12-17.
[47] Drug and Alcohol Services South Australia.: Opioid prescription in chronic painconditions.www.dassa.sa.gov.au/webdata/resources/ files/Opioid_prescription_chronic_pain_guidelines_for_SA_GPs_ALL. pdf. Accessed November 8, 2013.
[48] Dudgeon D, Raubertas RF, Rosenthal SN.: The Short–Form McGill Pain Questionnaire in Chronic Cancer Pain. J Pain Symptom Manage 1993; 8: 191-195.
[49] Dunn KM, Saunders KW, Rutter CM, Banta-Green CJ, Merrill JO, Sullivan MD, Weisner CM, Silverberg MJ, Campbell CI, Psaty BM, Von Korff M.: Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med 2010; 152: 85-92.
[50] Eisenberg E, McNicol ED, Carr DB.: Efficacy and safety of Opioid Agonists in the Treatment of Neuropathic pain of Nonmalignant Origin: Systematic Review and Meta-analysis of Randomized Controlled Trials. JAMA 2005; 22; 293(24): 3043-3052.
[51] Eisenberg E, McNicol ED, Carr DB.: Efficacy of mu-opioid agonists in the treatment of evoked neuropathic pain: Systematic review of randomized controlled trials. Eur J Pain 2006; 10(8): 667-676. Epub 2005 Dec 5.
[52] Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sandor PS.: EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force. European Journal of Neurology 2009; 16: 968- 981 doi:10.1111/j.1468-1331.2009.02748.x
[53] Farrar JT, Young Jr. JP, LaMoreaux L, Werth J, Poole RM.: Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001; 94: 149-158.
[54] Fishbain DA, Cole B, Lewis J, Rosomoff HL, Rosomoff RS.: What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-relat ed behaviors? A structured evidence-based review. Pain Medicine 2008; 9(4): 444-459.
[55] Fishman SM, Wilsey B, Yang J, Reisfield GM, Bandman TB, Borsook D.: Adherence monitoring and drug surveillance in chronic opioid therapy. Journal of Pain & Symptom Management 2000; 20(4): 293-307.
[56] Franklin GM.: Opioids for chronic noncancer pain: a position paper of the American Academy of Neurology. Neurology 2014: 83: 1277- 1284.
[57] Freye E, Anderson-Hillemacher A, Ritzdorf I, Levy JV.: Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients. Pain pract 2007; 7: 123-129.
[58] Friedmann N, Klutzaritz V, Webster L.: Efficacy and safety of an extended-release oxycodone (Remoxy) formulation in patients with moderate to severe osteoarthritic pain. J Opioid Manag 2011; 7(3): 193-202.
[59] Furlan AD, Pennick V, Bombardier C, van Tulder M.: 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group. Spine 2009; 15; 34(18): 1929-1941.
[60] Furlan AD, Reardon Dip R, Weppler C.: For the National Opioid Use Guideline Group (NOUGG). Opioids for chronic noncancer pain: a new Canadian practice guideline. CMAJ 2010; 15, 182(9).
[61] Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E.: Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ 2006; 23; 174(11): 1589-1594.
[62] Gaskell H, Moore RA, Derry S, Stannard C.: Oxycodone for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2014; 23; 6:CD010692. doi: 10.1002/14651858.CD010692.pub2.
[63] Gatti A, Sabato AF, Occhioni R, Colini Baldeschi G, Reale C.: Controlled-release oxycodone and pregabalin in the treatment of neuropathic pain: results of a multicenter Italian study. Eur Neurol 2009; 61(3): 129-37. doi: 10.1159/000186502. Epub 2008 Dec 18.
[64] Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL.: Morphine, gabapentin, or their combination for neuropathic pain. New England Journal of Medicine 2005; 31; 352(13): 1324-1334.
[65] Gimbel JS, Richards P, Portenoy RK.: Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology 2003; 60: 927-934.
[66] Gomes T, Mamdani MM, Dhalla IA, Paterson JM, Juurlink DN.: Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med 2011; 171: 686-691.
[67] Gordon A, Callaghan D, Spink D. et al.: Buprenorphine transdermal system in adults with chronic low back pain: a randomized, double blind, placebo-controlled crossover study, followed by an open-label extension phase. Clin Ther 2010; 32(5): 844-860.
[68] Graham C, Bond SS, Gerkovich MM, Cook MR.: Use of the McGill Pain Questionnaire in the assessment of cancer pain: replicability and consistency. Pain 1980; 8: 377-387.
[69] Graziotti P, Goucke R.: The use of oral opioids in patients with chronic nonmalignant pain: Management strategies. Perth, Australia: Australian Pain Society; 2002.
[70] Hale ME, Ahdieh H, Ma T, Rauck R.: Efficacy and Safety of OPANA ER (Oxymorphone Extended release) for Relief of Moderate to Severe Chronic Low Back Pain in Opioid-Experienced Patients: A 12-Week, Randomized,Double-blind, Placebo-controlled Study. Journal of Pain 2007; 8(2): 175-184.
[71] Hale M, Khan A, Kutch M, Li S.: Once-daily OROS hydromorphone ER compared with placebo in opioidtolerant patients with chronic low back pain. Curr Med Res Opin 2010; 26(6): 1505-1518.
[72] Harle CA, Bauer SE, Hoang HQ, Cook RL, Hurle y RW, Fillingim RB.: Decision support for chronic pain care: how do primary care physicians decide when to prescribe opioids? a qualitative study. BMC Fam Pract. 2015; 14(16): 48. doi: 10.1186/s12875-015- 0264-3.
[73] Häuser W, Bock F, Engeser P, Tölle T, Willweber-Strumpf A, Petzke F.: Clinical practice guideline: Long-term opioid use in non-cancer pain. Dtsch Arztebl Int 2014; 111: 732-740. DOI: 10.3238/arztebl. 2014.0732
[74] Häuser W, Bock F, Engeser P, Hege-Scheuing G, Hüppe M, Lindena G, Maier C, Norda H, Radbruch L, Sabatowski R, Schäfer M, Schiltenwolf M, Schuler M, Sorgatz H, Tölle T, Willweber-Strumpf A, Petzke F.: Recommendations of the updated LONTS guidelines: Long-term opioid therapy for chronic noncancer pain]. Schmerz 2015 [A]; 29(1): 109-30. doi: 10.1007/s00482-014-1463-x. German.
[75] Häuser W, Bernardy K, Maier C.: Long-term opioid therapy in chronic noncancer pain : A systematic review and meta-analysis of efficacy, tolerability and safety in open-label extension trials with study duration of at least 26 weeks]. Schmerz 2015[B]; 29(1): 96-108. doi: 10.1007/s00482-014-1452-0. German.
[76] Hegmann KT, Weiss MS, Bowden K, Branco F, DuBrueler K, Els C, Mandel S, McKinney DW, Miguel R, Mueller KL, Nadig RJ, Schaffer MI, Studt L, Talmage JB, Travis RL, Winters T, Thiese MS, Harris JS.: ACOEM practice guidelines: opioids for treatment of acute, subacute, chronic, and postoperative pain. J Occup Environ Med 2014; 56(12): e143-59. doi: 10.1097/JOM.0000000000000352.
[77] Hilgier M.: Ból u chorego na nowotwór i jego leczenie. Terapia 2003; 6 (1): 3-9.
[78] Ho KY, Chua NH, George JM.: Pain Association of Singapore Task Force. Evidence-based guidelines on the use of opioids in chronic non-cancer pain-a consensus statement by the Pain Association of Singapore Task Force. Ann Acad Med Singapore 2013; 42: 138-152.
[79] Huse E, Larbig W, Flor H. et al.: The effect of opioids on phantom limb pain and cortical reorganization. Pain 2001; 90: 47-55.
[80] IASP Subcommittee on Taxonomy.: Pain terms: a list with definitions and notes of usage. Pain 1980; 8: 249-252.
[81] Ingham JM, Portenoy RK.: The measurement of pain and other symptoms. W: Doyle D, Hanks G, Cherny N, Kalman K. [ed.]: Oxford Textbook of Palliative Medicine. Oxford University Press, Oxford 2004: 167-184.
[82] Institute for Clinical Systems Improvement.: Health care guideline: diagnosis and treatment of headache. Retrieved April 13, 2012, from http://www.icsi.org/headache/headache__diagnosis_and_treatment_ of_2609.html.
[83] Kahan M , Mailis-Gagnon A, Wilson L, Srivastava A.: Canadian guideline for safe and effective use of opioids for chronic noncancer pain. Clinical summary for family physicians. Part 1: general population. Can Fam Physician 2011[A]; 57: 1257-1266.
[84] Kahan M, Mailis-Gagnon A, Wilson L, Srivastava A. Canadian guideline for safe and effective use of opioids for chronic noncancer pain. Clinical summary for family physicians. Part 2: special populations. Can Fam Physician 2011[B]; 57: 1269-1276.
[85] Kalso E, Allan L, Dellemijn PL. et al.: Recommendations for using opioids in chronic non-cancer pain. Eur J Pain 2003; 7(5): 381-386.
[86] Kalso E, Edwards JE, Moore RA, McQuay HJ.: Opioids in chronic non- -cancer pain: systematic review of efficacy and safety. Pain. 2004; 112: 372-380.
[87] Kapural L.: Chronic Abdominal Pain – An Evidence–Based, Comprehensive Guide to Clinical Management, Springer, New York 2015.
[88] Katz N, Hale M, Morris D.: Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain. Postgrad Med 2010; 122: 112-118.
[89] Katz N, Rauck R, Ahdieh H. et al.: A 12-week, randomized, placebo- -controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain. Curr Med Res Opin 2007; 23: 117-128.
[90] Kaye AD, Kaye AM, Urman RD.: Essentials of Pharmacology for Anesthesia, Pain Medicine and Critical, Springer, New York 2015.
[91] Khoromi S, Cui L, Nackers L, Max MB.: Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain. Pain 2007; 130: 66-75.
[92] Kostka–Trąbka E, Woroń J.: Interakcje leków w praktyce klinicznej. Wydawnictwo lekarskie PZWL, Warszawa 2011: 17.
[93] Krajnik M, Sobański P.: Standardy leczenia bólu w chorobie nowotworowej: drabina analgetyczna, miareczkowanie opioidów i postępowanie w przypadku działań niepożądanych analgetyków opioidowych. W: chory na nowotwór- kompendium leczenia bólu. (ed. Malec-Milewska M, Krajnik M, Wordliczek J). Med. Educ. Warszawa 2013: 179-195.
[94] Krumova EK, Bennemann P, Kindler D. et al.: Low pain intensity after opioid withdrawal as a first step of the comprehensive pain rehabilitation program predicts long-term nonuse of opioids in chronic noncancer pain. Clin J Pain 2013; 29: 760-769.
[95] Landau CJ, Carr WD, Razzetti AJ, Sessler NE, Munera C, Ripa SR.: Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance- of-analgesia study. Clin Ther 2007; 29(10): 2179-2193.
[96] Langford R, McKenna F, Ratcliffe S. et al.: Transdermal fentanyl for improvement of pain and functioning in osteoarthritis: a randomized, placebo-controlled trial. Arthritis Rheum 2006; 54(6): 1829-1837.
[97] Lauche R, Klose P, Radbruch L, Welsch P, Häuser W.: Opioids in chronic noncancer pain-are opioids different? A systematic review and meta-analysis of efficacy, tolerability and safety in randomized head- -to-head comparisons of opioids of at least four week’s duration. Schmerz 2015; 29(1): 73-84. doi: 10.1007/s00482-014-1432-4.
[98] Lazzari M, Sabato AF, Caldarulo C, Casali M, Gafforio P, Marcassa C, Leonardis F.: Effectiveness and tolerability of low-dose oral oxycodone/naloxone added to anticonvulsant therapy for noncancer neuropathic pain: an observational analysis. Curr Med Res Opin 2014; 30(4): 555-64. doi: 10.1185/03007995.2013.866545.
[99] Leppert W.: Emerging therapies for patients with symptoms of opioid–induced bowel dysfunction. Drug Des Develop Ther 2015; 9: 2215-2231.
[100] Leppert W, Majkowicz M.: Adaptacja Karty Oceny Bólu Memorial (Memorial Pain Assessment Card) do warunków polskich – propozycja standardowego narzędzia służącego do oceny bólu i monitorowania leczenia bólu u chorych na nowotwory. Med Paliat 2011; 3: 207-213.
[101] Leppert W, Majkowicz M.: Polish Brief Pain Inventory for pain assessment and monitoring of pain treatment in cancer patients. J Palliat Med 2010; 13: 663-668.
[102] Litt JZ.: Drug Eruption & Reaction Manual. CRC Press 2015.
[103] Manchikanti KN, McManus CD, Pampati V, Parr AT, Pasupuleti R, Patel V, Pope JE, Sehgal N, Silverman SM, Singh V, Smith HS, Solanki DR, Tracy DH, Vallejo R, Wargo BW.: American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 1 – Evidence assessment. Pain Physician 2012 [A]; 15: S1-S66.
[104] Manchikanti L, Abdi S, Atluri S, Balog CC, Benyamin RM, Boswell MV, Brown KR, Bruel BM, Bryce DA, Burks PA, Burton AW, Calodney AK, Caraway DL, Cash KA, Christo PJ, Damron KS, Datta S, Deer TR, Diwan S, Eriator I, Falco FJ, Fellows B, Geffert S, Gharibo CG, Glaser SE, Grider JS, Hameed H, Hameed M, Hansen H, Harned ME, Hayek SM, Helm S 2nd, Hirsch JA, Janata JW, Kaye AD, Kaye AM, Kloth DS, Koyyalagunta D, Lee M, Malla Y, Manchikanti KN, McManus CD, Pampati V, Parr AT, Pasupuleti R, Patel VB, Sehgal N, Silverman SM, Singh V, Smith HS, Snook LT, Solanki DR, Tracy DH, Vallejo R, Wargo BW.: American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2 - guidance. Pain Physician 2012 [B]; 15: S67-S116.
[105] Manchikanti L, Fellows B, Ajlinani H. et al.: Therapeutic use, abuse and nonmedical use of opioids: A ten-year perspective. Pain Physician 2010; 13: 401-435.
[106] Markenson JA, Croft J, Zhang PG, Richards P.: Treatment of persistent pain associated with osteoarthritis with controlled-release oxycodone tablets in a randomized controlled clinical trial. Clin J Pain 2005; 21(6): 524-535.
[107] Martell B.: Systematic review: Opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann Intern Med 2007; 146: 116-127.
[108] Matsumoto AK, Babul N, Ahdieh H.: Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placeboand active-controlled phase III trial. Pain Med 2005; 6(5): 357-366.
[109] McNicol ED, Midbari A, Eisenberg E.: Opioids for neuropathic pain. Cochrane Database Syst Rev 2013; 29; 8: CD006146. doi: 10.1002/14651858.CD006146.pub2.
[110] Melzack R.: The McGill Pain Questionnaire: Major properties and scoring methods. Pain 1975; 1: 277-299.
[111] Melzack R.: The short-form McGill Pain Questionnaire. Pain 1987; 30: 191-197.
[112] Michna E, Ross EL, Hynes WL. et al.: Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history. J. Pain Symptom Manage 2004; 28: 250-258.
[113] Moore RA, Derry S, Taylor RS, Straube S, Phillips CJ.: The costs and consequences of adequately managed chronic noncancer pain and chronic neuropathic pain. Pain Practice 2013.
[114] Moran C.: MST continus tablets and pain control in severe rheumatoid arthritis. British Jounal of Clinical Research 1991; 2: 1-12.
[115] Munera C, Drehobl M, Sessler NE, Landau C.: A randomized, placebo-controlled, double-blinded, parallel-group, 5-week study of buprenorphine transdermal system in adults with osteoarthritis. J Opioid Manag 2010; 6: 193-202.
[116] National Opioids Use Guideline Group (NOUGG). Canadian guidelines for safe and effective use of opioids for chronic non-cancer pain, Recommendations for Practice, Version 5.6. April 30, 2010. http:// nationalpaincentre.mcmaster.ca/documents/opioid_guideline_part_ b_v5_6.pdf Available: http://nationalpaincentre.mcmaster.ca/ opioid/Accessed November 8, 2013.
[117] Noble M, Treadwell JR, Tregear SJ, Coates VH, Wiffen PJ, Akafomo C, Schoelles KM.: Long-term opioid management for chronic noncancer pain (Review). The Cochrane Library 2010, Issue 1.
[118] Noble M, Tregear SJ, Treadwell JR, Schoelles K.: Long-term opioid therapy for chronic noncancer pain: A systematic review and meta- -analysis of efficacy and safety. J Pain Symptom Manage 2008; 35: 214-228.
[119] Nüesch E, Rutjes AW, Husni E, Welch V, Jüni P.: Oral or transdermal opioids for osteoarthritis of the knee or hip. Cochrane Database Syst Rev 2009; 7(4): CD003115. doi: 10.1002/14651858.CD003115.pub3.
[120] Palmera RE, Carrellb DS, Cronkiteb D, Saundersb K, Grossa DE, Mastersa E, Donevana S, Hylana TR, Von Korff M.: The prevalence of problem opioid use in patients receiving chronic opioid therapy: computer- assisted review of electronic health record clinical notes Pain. 2015 Jul;156(7):1208-14 doi: 10.1097/j.pain.0000000000000145
[121] Passik SD, Kirsh KL.: The need to identify predictors of aberrant drug- -related behavior and addiction in patients being treated with opioids for pain. Pain Medicine 2003; 4: 186-189.
[122] Paulozzi LJ, Weisler RH, Patkar AA. et al.: A national epidemic of unintentional prescription opioid overdose deaths: How physicians can help control it. J Clin Psychiatry 2011; 72: 589-592.
[123] Pérez C, Margarit C, Serrano M.: Spanish group of CHANGE PAIN patient survey: Survey of European patients assessing their own noncancer chronic pain: results from Spain. Current Medical Research and Opinion 2013; 29: 643-651.
[124] Petzke F, Welsch P, Klose P, Schaefert R, Sommer C, Häuser W.: Opioids in chronic low back pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration. Schmerz. 2015; 29(1): 60-72. doi: 10.1007/s00482-014-1449-8.
[125] Pink LR, Smith AJ, Peng PW, Galonski MJ, Tumber PS, Evans D, Gourlay D, Gordon L, Bellingham G, Nijjar SS, Picard LM, Gordon AS.: Intake assessment of problematic use of medications in a chronic noncancer pain clinic. Pain Res Manage 2012; 17: 276-280.
[126] Portenoy RK, Portenoy RK.: Opioid therapy for chronic nonmalignant pain: a review of the critical issues. J Pain Sympt Manage 1996; 11(4): 203-217.
[127] Provenzano DA, Viscusi ER.: Rethinking the role of opioids in the outpatient management of chronic nonmalignant pain. Curr Med Res Opin 2014; 30(10): 2051-62. doi: 10.1185/03007995.2014.921610. Epub 2014 Jun 18.
[128] Pyszkowska J.: Możliwości oceny bólu przewlekłego. Próba obiektywizacji oceny bólu za pomocą zmodyfikowanego arkusza oceny bólu. Psychoonkol 1999; 4: 13-27.
[129] Radbruch L, Loick G, Kiencke P, Lindena G, Sabatowski R, Grond S, Lehmann KA, Cleeland CS.: Validation of the German Version of the Brief Pain Inventory. J Pain Symptom Manage 1999; 18: 180-187.
[130] Raja SN, Haythornthwaite JA, Pappagallo M. et al.: Opioids versus antidepressants in postherpetic neuralgia a randomized, placebo- -controlled trial. Neurology 2002; 59: 1015-1021.
[131] Rauck R, Rapoport R, Thipphawong J.: Results of a double-blind, placebo-controlled, fixed-dose assessment of once-daily OROS® hydromorphone ER in patients with moderate to severe pain associated with chronic osteoarthritis. Pain Pract 2013; 13(1): 18-29.
[132] Reid MC, Engles-Horton LL, Weber MB. et al.: Use of opioid medications for chronic noncancer pain syndromes in primary care. J. Gen. Intern. Med 2002; 17: 173-179.
[133] Roth SH, Fleischmann RM, Burch FX, Diet ZF, Bockow B, Rapoport RJ. et al.: Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation. Archives of Internal Medicine 2000; 27; 160(6): 853-860.
[134] Saunders K, Shortreed S, Thielke S, Turner JA, LeResche L, Beck R, Von Korff M.: Evaluation of Health Plan Interventions to Influence Chronic Opioid Therapy Prescribing. Clin J Pain 2015; 23. [Epub ahead of print].
[135] Saunders K, Von Korff M, Campbell CI, Banta-Green CJ, Sullivan MD, Merrill JO, Weisner C.: Concurrent Use of Alcohol and Sedatives among Persons Prescribed Chronic Opioid Therapy: Prevalence and Risk Factors. J Pain 2012; 13(3): 266-275. doi: 10.1016/j. pain.2011.11.004.
[136] Savage SR, Savage SR.: Long-term opioid therapy: assessment of consequences and risks. J Pain Sympt Manage 1996; 11(5): 274- 286.
[137] Schaefert R, Welsch P, Klose P, Sommer C, Petzke F, Häuser W.: Opioids in chronic osteoarthritis pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo- controlled studies of at least 4 weeks duration. Schmerz 2015; 29(1): 47-59. doi: 10.1007/s00482-014-1451-1.
[138] Sehgal N, Manchikanti l, Smith HS.: Rescription opioid Abuse in Chronic Pain: A Review of Opioid Abuse Predctiors and Strategies to Curb Opioid Abuse. Pain Physician 2012; 15: ES67-ES92.
[139] Sommer C, Welsch P, Klose P, Schaefert R, Petzke F, Häuser W.: Opioids in chronic neuropathic pain. A systematic review and meta- -analysis of efficacy, tolerability and safety in randomized placebo- -controlled studies of at least 4 weeks duration. Schmerz 2015; 29(1): 35-46. doi: 10.1007/s00482-014-1455-x.
[140] Stanos SP, Bruckenthal P, Barkin RL.: Subsequent Abuse of Longacting Opioids: Potential Risks and Benefits of Formulations with Physical or Pharmacologic Deterrents to Tampering. Mayo Clin Proc 2012; 87: 683-694. Technology Evaluation Center: Special Report: Chronic Noncancer Pain-Long-Term Opioid Benefits and Harms. Assessment Program Volume 27; 1, 2012.
[141] Stein C, Baerwald C.: Opioids for the treatment of arthritis pain. Expert Opin Pharmacother 2014; 15(2): 193-202. doi: 10.1517/14656566.2014.861818. Epub 2013 Nov 27. Review.
[142] Steiner DJ, Sitar S, Wen W. et al.: Efficacy and safety of the seven- -day buprenorphine transdermal system in opioid-naive patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study. J Opioid Manag 2011; 42(6): 903-917.
[143] Szatanik K.: Kwestionariusz bólowy–założenia, budowa kwestionariusza, wyniki przeprowadzonych badań. V Konferencja Sekcji Badania i Leczenia Bólu Polskiego Towarzystwa Anestezjologii i Intensywnej Terapii. Poznań–Błażejewko 1995.
[144] Szczudlik A, Dobrogowski J, Wordliczek J, Stępień A, Krajnik M, Leppert W, Woroń J, Przeklasa-Muszyńska A, Kocot-Kępska M, Zajączkowska R, Janecki M, Adamczyk A, Malec-Milewska M.: Rozpoznanie i leczenie bólu neuropatycznego: przegląd piśmiennictwa i zalecenia Polskiego Towarzystwa Badania Bólu i Towarzystwa Neurologicznego - część pierwsza. Ból, 2014; 15(2): 6-17.
[145] Szczudlik A, Dobrogowski J, Wordliczek J, Stępień A, Krajnik M, Leppert W, Woroń J, Przeklasa-Muszyńska A, Kocot-Kępska M, Zajączkowska R, Janecki M, Adamczyk A, Malec-Milewska M.: Rozpoznanie i leczenie bólu neuropatycznego: przegląd Neurologicznego - część druga. Ból, 2014; 15(3): 8-22.
[146] Taylor R Jr, Raffa RB, Pergolizzi JV Jr.: Controlled release formulation of oxycodone in patients with moderate to severe chronic osteoarthritis: a critical review of the literature. J Pain Res 2012; 5: 77-87. doi: 10.2147/JPR.S21965. Epub 2012 Apr 23.
[147] Technology Evaluation Center: Special Report: Chronic Noncancer Pain- Long-Term Opioid Benefits and Harms. Assessment Program Volume 27, No.1 October 2012.
[148] Trescot AM, Boswell MV, Atluri SL. et al.: Opioid guidelines in the management of chronic non-cancer pain. Pain Physician 2006; 9(1): 1-39.
[149] Turk DC, Okifuji A.: Assessment of patients’ reporting of pain: an integrated perspective. Lancet 1999; 353: 1784-1788.
[150] Ueberall MA, Mueller-Schwefe GH.: Safety and efficacy of oxycodone/ naloxone vs. oxycodone vs. morphine for the treatment of chronic low back pain: results of a 12 week prospective, randomized, open-label blinded endpoint streamlined study with prolonged-release preparations. Curr Med Res Opin 2015; 31(7): 1413-1429. doi: 10.1185/03007995.2015.1047747. Epub 2015 May 29.
[151] Uki J, Mendoza T, Cleeland CS, Nakamura Y, Takeda F.: A Brief Cancer Pain Assessment Tool in Japanese: The Utility of the Japanese Brief Pain Inventory–BPI–J. J Pain Symptom Manage 1998; 16: 364-373.
[152] Wang H, Akbar M, Weinsheimer N. et al.: Longitudinal observation of changes in pain sensitivity during opioid tapering in patients with chronic low-back pain. Pain Med 2011; 12: 1720-1726.
[153] Watson CP, Babul N.: Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 1998; 50: 1837-1841.
[154] Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J.: Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 2003; 105: 71-78.
[155] Webster LR, Butera PG, Moran LV. et al.: Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain. J Pain 2006; 7(12): 937-946.
[156] Welsch P, Sommer C, Schiltenwolf M, Häuser W. In.: Opioids in chronic noncancer pain-are opioids superior to nonopioid analgesics? A systematic review and meta-analysis of efficacy, tolerability and safety in randomized head-to-head comparisons of opioids versus nonopioid analgesics of at least four week’s duration. Schmerz 2015; 29(1): 85-95. doi: 10.1007/s00482-014-1436-0.
[157] White AP, Arnold PM, Norvell DC, Ecker E, Fehlings MG.: Pharmacologic management of chronic low back pain: synthesis of the evidence. Spine (Phila Pa 1976). 2011; 1, 36(21 Suppl): S131-43. doi: 10.1097/BRS.0b013e31822f178f.
[158] Whittle SL, Richards BL, Husni E, Buchbinder R.: Opioid therapy for treating rheumatoid arthritis pain. Cochrane Database Syst Rev 2011; 9(11): CD003113. doi: 10.1002/14651858.CD003113.pub3.
[159] Whittle SL, Richards BL, van der Heijde DM, Buchbinder R.: The efficacy and safety of opioids in inflammatory arthritis: a Cochrane systematic review. J Rheumatol Suppl 2012; 90: 40-6. doi: 10.3899/ jrheum.120341.
[160] Won A, Lapane K, Vallow S. et al.: Persistent nonmalignant pain and analgesic prescribing practice in elderly nursing home residents. J Am Geriatric Society 2004; 52: 867-874.
[161] Wörz R, Frank M, Achenbach U.: Controlled release oxycodone – A therapeutic option for severe neuropathic pain. Two multicenter observational studies. MMW Fortschr Med 2003; 145(suppl 3): 71-76.
[162] Wu CL, Agarwal S, Tella PK, Klick B, Clark MR, Haythornthwaite JA. et al.: Morphine versus mexiletine for treatment of postamputation pain: a randomized, placebo-controlled, crossover trial. Anesthesiology 2008; 109(2): 289-296.
[163] www.er-la-opioidrems.com; extended-release (er) and long-acting (la) opioid analgesics risk evaluation and mitigation strategy (rems). Initial rems approval: 07/2012 most recent modification: 12/2014.
[164] Vojtaššák J, Vojtaššák J, Jacobs A. et al.: A phase III b, multicentre, randomised, parallel-group, placebo-controlled, double-blind study to investigate the efficacy and safety of OROS hydromorphone in subjects with moderate-to-severe chronic pain induced by osteoarthritis of the hip or the knee. Pain Res Treat 2011: 239501.
[165] Vondrackova D, Leyendecker P, Meissner W. et al.: Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain 2008; 9(12): 1144-1154.
[166] Zajączkowska R, Dobrogowski J, Wordliczek J.: Zastosowanie leków opioidowych w leczeniu bólu pochodzenia nienowotworowego. W: Leczenie Bólu. (red. Wordliczek J, Dobrogowski J), PZWL Warszawa 2011: 66-76.